Table 1.
Baseline characteristics of study participants.
| Number | 33 | 13 | 7 | 6 | 4 | 5 | 7 | 6 | 13 | P |
| Vaccine | Vivotif | Vivotif | Rotarix | Rotarix | Opvero | Opvero | Dukoral | Dukoral | None | |
| ATRA | + | − | + | − | + | − | + | − | + | |
| Age (years) | 34 (22–42) | 38 (29–40) | 21 (19–25) | 39 (27–53) | 29 (25–33) | 20 (19–42) | 31 (28–40) | 39 (37–40) | 28 (22–43) | 0.43 |
| HIV Positive (n) | 5 | 2 | 0 | 1 | 1 | 1 | 3 | 4 | 3 | |
| BMI (kg/m2) | 20 (19–23) | 22 (19–23) | 20 (19–21) | 20 (19–20) | 21 (19–24) | 19 (17–25) | 20 (18–24) | 19 (18–19) | 19 (18–24) | 0.43 |
The number of participants randomised to Vivotif includes those in the time course experiments, vaccine comparison experiments and pIgR experiments. Volunteers were all healthy adult men randomised to receive one or none of the vaccines with or without 10 mg ATRA given daily for 8 days. For vaccine comparisons 8 volunteers were recruited, pIgR studies had 13 volunteers while the time course studies had 12 volunteers all given Vivotif + ATRA. These are shown as pooled Vivotif vaccine groups. Continuous variables are shown as median and interquartile range (IQR). ATRA: all-trans retinoic acid, BMI: body mass index.